Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib for Thyroid Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recent diagnosis of thyroid eye disease (within the past 3 months)~* Have ocular symptoms or signs of TED with a clinical activity score (CAS) of at least 3~Exclusion Criteria:~* Pregnancy~* Previous treatment with corticosteroid for TED for \>2wks~* Previous treatment with orbital radiation for TED~* Impaired renal function~* Impaired hepatic function~* Treatment with antihypertensive medications except beta-blockers~* History of congestive heart failure, cardiac valvular disease, or coronary artery disease~* Allergy to NSAID or previous adverse reaction (ie. GI bleeding)~* Vision loss due to compressive optic neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
- Control (Type: ACTIVE_COMPARATOR): Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)

Based on this trial design, predict the completion outcome and termination type (if applicable).